Indivior Pharmaceuticals Inc.

INDV Healthcare Drug Manufacturers Specialty & Generic

Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS grew 580.0%, free cash flow grew 58.6% and total debt rose 49.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

32.45 1.17 −3.48%
Market cap
$4.0B
P/E
11.2×
Fwd P/E
11.8×
Dividend yield
0.00%
F-score
4/9
Altman Z
3.28
Beneish M
−1.52
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
4 5 4 7

+8 more TTM periods

ROE
(153.12%) (117.21%) (96.33%) (68.45%)
ROA
26.52% 19.60% 16.69% 8.89%
ROIC
460.53% 124.25% 629.81% 0.00%
Return on Tangible Assets
1,873.68% 560.00% (177.97%) 158.02%
Average Days of Receivables
78.70 80.64 75.12 84.14
Free Cash Flow per Share
(0.93) (1.55) (0.76) 0.94
Free Cash Flow
(111.00) (192.00) (95.00) 117.00
Capital Expenditures
(71.00) (81.00) (68.00) (60.00)
Other line items
Cash ROIC
(22.16%) (37.14%) (22.84%) 20.89%
Accounts Receivable Turnover
5.02 4.63 4.57 4.35
Accounts Payable Turnover
1.19 1.34 1.06 0.44
Inventory Turnover
1.61 1.54 1.54 1.36
Average Days of Payables
313.29 268.47 370.94 345.70
Days of Inventory on Hand
228.13 229.26 227.01 249.23
Tax Rate
(0.10) (0.15) (0.12) (0.34)
Research and Development Expense of Revenue
6.16% 7.05% 7.83% 9.07%
Selling, General and Administrative Expense of Revenue
44.25% 48.45% 51.17% 52.63%
Share Based Compensation of Revenue
2.40% 2.25% 2.10% 2.29%
Interest Coverage
15.56 8.30 5.82 4.45
Operating CF/Net income
(0.11) (0.44) (0.13) 1.38
Depreciation/Fixed assets
0.10 0.12 0.14 0.19
Capex/Depreciation
(4.18) (4.26) (3.40) (2.50)
Revenue per Share
11.18 10.40 9.91 9.44
Operating CF per Share
(0.34) (0.90) (0.22) 1.42
Capex per Share
(0.60) (0.65) (0.54) (0.48)
Capex to Sales
0.05 0.06 0.05 0.05

Fold the line items

Columns are period end dates · fundamentals updated 2 Oct 2026